Evidence map›Paper›PMID 41108334›Full record

ReviewDigestive diseases and sciences2026

Similar Symptoms, Distinct Syndromes: Multi-modal Approach to the Patient with an IBD-IBS Overlap.

Andrew Chang, Janice Oh, Andrea Shin, Megan Oser, Natalie Manitius, Amir Ghaffari, Berkeley N Limketkai

Abstract readReview
PubMed Publisher
In one paragraph

Review in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. VSL#3Nutrients · 2026
    Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrew ChangVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, UCLA School of Medicine, Los Angeles, 757 Westwood Plaza, Los Angeles, CA, 90095, USA. andchang@mednet.ucla.edu.
Janice OhVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, UCLA School of Medicine, Los Angeles, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
Andrea ShinVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, UCLA School of Medicine, Los Angeles, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
Megan OserVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, UCLA School of Medicine, Los Angeles, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
Natalie ManitiusVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, UCLA School of Medicine, Los Angeles, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
Amir GhaffariVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, UCLA School of Medicine, Los Angeles, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
Berkeley N LimketkaiVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, UCLA School of Medicine, Los Angeles, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are distinct gastrointestinal conditions, but they frequently share overlapping clinical symptoms such as abdominal pain, bloating, and altered bowel habits. IBD is defined by the presence of chronic immune-mediated inflammation, and IBS is characterized by gastrointestinal symptoms in the absence of endoscopic and histologic inflammation. When patients with IBD continue to experience IBS-like symptoms despite remission of inflammation, this phenomenon is commonly referred to as IBD-IBS overlap. These patients pose diagnostic and therapeutic challenges, as symptom persistence may reflect lingering immune activation, disrupted barrier function, visceral hypersensitivity, gut-brain axis dysfunction, or microbiome alterations. This review synthesizes emerging evidence on the shared mechanisms underlying IBD and IBS and outlines a multimodal treatment approach that includes pharmacologic management, dietary interventions, mind-body therapies, and microbiome-directed strategies such as probiotics and fecal microbiota transplantation.

Indexed as

Inflammatory Bowel DiseasesIrritable Bowel SyndromeCombined Modality TherapyFecal Microbiota TransplantationGastrointestinal MicrobiomeHumansProbioticsDietary interventionsFecal microbiota transplantationInflammatory bowel diseaseIrritable bowel syndrome

Identifiers

PMID41108334

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.